Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04437537 · ClinicalTrials.gov registry record · NA
Pilot Study of PHOENIX Wound Matrix® Impact on Chronic DFU Wound Microbiome
A NA study of Diabetic Foot Ulcer, sponsored by RenovoDerm.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT04437537: Completed NA study of Diabetic Foot Ulcer, sponsored by RenovoDerm.
NCT04437537 is a NA study of Diabetic Foot Ulcer that has completed, run by RenovoDerm. The registered enrollment target is 11 participants, below the 255-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04437537, a NA study of Diabetic Foot Ulcer, has completed, sponsored by RenovoDerm.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
A Pilot Study to Determine the Impact of the Phoenix Wound Matrix® on the Wound Microbiome in Chronic Diabetic Foot Ulcers
Primary Outcome
Analysis of the wound microbiome in subjects with chronic DFUs prior to PHOENIX application and at follow-up Study Visits 3, and possibly 5 (if debridement is deemed necessary by the Investigator), again prior to the application of PHOENIX. This analysis will identify and quantify bacterial and fungal microorganisms present in the wound bed.
Conditions Studied
Interventions
- DEVICE Bioresorbable 3D electrospun synthetic matrix
Study Locations (1)
Pennsylvania
- PA Foot & Ankle Associates - Northampton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2025-07-21 |
| Phase | NA |
What the finished NCT04437537 record still lists
NCT04437537 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 255-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 1 intervention - of which Bioresorbable 3D electrospun synthetic matrix is the first listed.
NCT04437537 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04437537 about?
NCT04437537 is a clinical study titled "Pilot Study of PHOENIX Wound Matrix® Impact on Chronic DFU Wound Microbiome". A Pilot Study to Determine the Impact of the Phoenix Wound Matrix® on the Wound Microbiome in Chronic Diabetic Foot Ulcers
What is the current status of trial NCT04437537?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2025-03-21. Estimated completion is 2025-07-21.
What conditions does trial NCT04437537 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer.
What interventions are being tested in trial NCT04437537?
The interventions under investigation include: Bioresorbable 3D electrospun synthetic matrix (DEVICE).
Who is sponsoring clinical trial NCT04437537?
This trial is sponsored by RenovoDerm, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04437537 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04437537's enrollment target sits among peer trials
11 66th of 67 higher than 2 of 67 other Diabetic Foot Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
RECRUITING · NA
-
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
RECRUITING · NA
-
Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
RECRUITING · NA
-
Exercise Enhances Wound Healing in Patients With Diabetic Foot Ulcers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI